Multifocal motor neuropathy: 30 years from onset to diagnosis

L. Hobson‐Webb,Stephen N. Donahue,R. Bey

DOI: https://doi.org/10.1002/mus.24968

2016-03-01

Abstract:toes, and no Romberg sign. Nerve conduction study (NCS) was consistent with a distal demyelinating sensory and motor polyneuropathy (Table 1) and suspicious for anti-MAG polyneuropathy. Serum protein electrophoresis revealed an IgM-kappa monoclonal gammopathy with a concentration of 0.2 g/dl and an anti-MAG antibody titer of 1:25,600 (normal< 1:1,600; Athena Diagnostics). The skeletal survey was normal, and the patient declined bone marrow biopsy. The patient was treated intravenously with rituximab 375 mg/m weekly for 4 treatments and, within 1 month, she reported substantial improvement of symptoms. Repeat NCS at 4 and 7 years after treatment performed by a neuromuscular neurologist using the same techniques showed marked interval improvement with no signs of demyelination on the most recent study (Table 1). Her paraprotein level has been undetectable since treatment, allaying concerns about an occult hematologic malignancy, and her total IgM level consistently decreased from baseline. Her antiMAG antibody titer, which decreased substantially after rituximab to <1:1,600, has only recently started to increase again (Table 1). Seven years after treatment, she reports only limited numbness in the toes and has a normal neurological examination. This case is notable as it highlights a marked improvement of demyelination in anti-MAG neuropathy. This finding was evident on electrodiagnostic testing, correlated with clinical improvement, and has persisted over many years after a single course of treatment with rituximab. We speculate that the remarkable response to treatment in this patient may be explained by early detection of her disease and the lack of secondary axonal degeneration. Few previous rituximab trials in patients for anti-MAG neuropathy have incorporated electrophysiological parameters. A study of 7 patients with anti-MAG neuropathy failed to demonstrate any changes in electrophysiological parameters with rituximab therapy. However, another recent report demonstrated improvement in 23 of 45 patients treated with immunotherapy for anti-MAG neuropathy. Given those earlier results and the findings in our patient, incorporating electrodiagnostic parameters as end-points in future studies may be of value in definitively identifying a meaningful response to rituximab in this disease.